Interactions with Drugs and Dietary Supplements Used For Weight Loss by Jordan, Melanie A.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Interactions with Drugs and Dietary Supplements Used
For Weight Loss
Melanie A.  Jordan
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/51145
1. Introduction
Obesity and overweight have increasingly become major global health issues. Data from the
World Health Organization (WHO) reports a near doubling of the prevalence of obesity
worldwide from 1998 to 2008 [1]. In the European Region, an average of over 50% of adults
are overweight and nearly 23% obese, with the prevalence of overweight and obesity being
highest in Finland (67.1%), Germany (67.2%), the United Kingdom (67.8%), Malta (73.3%), and
Greece (77.5%) [2]. Similar alarming trends are seen in the United States NHANES data where
68% of adults have a body mass index (BMI) greater than 25 (overweight or obese) and nearly
37% of the population is considered obese [3-7]. A large burden of health care costs can be
attributed to overweight and obesity since multiple disease states such as diabetes, cancer,
heart disease can be linked overweight and obesity [8-10]. The WHO estimates that up to 6%
of health care expenditures in the European Region, while estimates for the United States have
been estimated at 5.7% of the National Health Expenditure [8-11]. Most major organizations,
like the WHO, and governmental agencies such as the U.S. Department of Agriculture Center
for Nutrition Policy and Promotion have a major focus on the treatment of the obesity epidemic
through promotion of proper healthy lifestyle changes [11, 12]. Although multiple anti-obesity
agents have progressed through the development process, few drug products have made it
through the approval process due to safety or lack of efficacy concerns. Several products, such
as amphetamine, fenfluramine and sibutramine, have had their approval removed and/or have
been removed from the market following reports linking the drugs to cardiovascular side
effects (e.g. hypertension and myocardial infarction), addiction, and death [13-15]. As an
alternative, overweight or obese patients may turn to less regulated dietary supplements as a
means to assist in weight loss. Multiple herbal products are available that are indicated, often
without significant scientific basis, for the treatment of overweight and obesity. The safety and
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efficacy of herbal products is often unknown, especially given the presence of multiple
chemical compounds, lack of known active constituents or lack of standardization of known
compounds [16-19].This chapter presents a review of the chemistry and pharmacology of
approved anti-obesity drug products, the proposed mechanism of action for common dietary
supplements used in the management of weight loss, and potential drug-drug or herb-drug
interactions.
2. Drugs used in weight LOcSS
2.1. Sympathomiometic agents
2.1.1. Diethylpropion hydrochloride (Tenuate®; Tenuate® Dospan®; Durad®)
Diethylpropion HCl (amfepramone, Figure 1a) is a sympathomimetic aminoketone agent with
some similarity both chemically and pharmacologically to amphetamines and other related
stimulant drugs. Similarly to amphetamine, diethylpropion stimulates release while inhibiting
reuptake of dopamine, norepinephrine, and 5-hydroxytryptamine [20, 21]. The increase in
norepinephrine and dopamine levels along with inhibition of their reuptake is proposed as
the mechanism of diethylpropion anorectic effects [22]. Diethylpropion is indicated for short
term management of obesity in patients with a body mass index (BMI) of > 30 kg/m2 who have
not responded to diet and exercise alone [23]. Because of its similarity to amphetamine, some
patients become psychologically dependent on diethylpropion with an increased risk of self-
medicating at higher dosages, increasing potential for drug interactions.
Diethylpropion is a monoamine and therefore can interact with monoamine oxidase inhibitors
(MAOI), resulting in hypertension [23]. The manufacturer recommends avoiding use of
diethylpropion during or within 14 days of discontinuation of MAOI administration. There is
also one reported case of diethylpropion -induced psychosis in a 26 year old female patient
taking phenelzine [24]. The authors hypothesized that chronic diethylpropion use led to an
increased sensitivity to MAOI psychosis-inducing effects. Although the additive effects of
diethylpropion in combination with other anorectic agents has not been studied, combined
use of these agents is contraindicated due to the potential increased risk of cardiovascular
issues [23]. In an early study of diethylpropion in 32 obese hypertensive patients, a drop in
blood pressure was observed [25]. However, it was unclear if the drop in blood pressure in
these subjects was due to weight loss or the additive effect of additional hypertensive agents
that the patients were taking. The manufacturer also recommends potential modification of
insulin dosing, although no strong evidence to support this statement can be found. In one
study done in the rat, it was determined that anorectic drugs acting via the dopaminergic
system antagonize hyperphagia induced by 2-deoxy-D-glucose, although the authors did not
find any modifications to insulin-induced hypoglycemia [26]. There are no reported cases of
drug-herb interactions with diethylpropion. However, theoretically herbal products with CNS
stimulant properties (e.g. ephedra, caffeine, bitter orange), potential for interaction with
sympathomimetic agents (e.g. Indian snakeroot), or MAOI activity (e.g. yohimbe) should be
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avoided due to an increased risk of hypertension, cardiovascular effects, and changes in blood
pressure [27].
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Figure 1. Molecular structures of anorectic drugs.
2.1.2. Phentermine / Phentermine hydrochloride (Fastin®, Ionamin®, Adipex-P®, Suprenza®)
Phentermine (Figure 1b), a member of the β-phenylethylamine family of compounds, exerts
anorectic activity centrally through appetite suppression and is indicated in the short term
treatment of obesity in patients with a BMI ≥ 30 kg/m2 [28]. A meta-analysis of six randomized
controlled trials of phentermine cumulatively show an added 3.6 kg weight loss over 2 to 24
weeks compared to control groups [29]. Phentermine acts by increasing the release of and
inhibiting the reuptake of norepinephrine or dopamine [22]. Although one of the oldest
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approved anti-obesity drugs, the safety of monotherapy of phentermine is relatively scarce
due to the long history of combination products, most notably phentermine/fenfluramine
(Phen-Fen), which was removed from the market due to serious and potentially fatal cardio‐
vascular effects [30, 31]. More recently a combination product containing phentermine and
topiramate has been investigated (see Topiramate below) and is currently under review by the
US Food and Drug Administration (FDA).
Because of the similarity in activity and mechanism of action, drug interactions with phenter‐
mine are similar to those for diethylpropion (see Diethylpropion above) including avoidance of
alcohol, potential changes to antidiabetic agent therapy, and avoidance of coadministration of
MAOIs [28]. There is one case report of a female patient experiencing two penropative
hypertensive crises, which were attributed to an interaction between phentermine and
anesthetic agents [32].
2.2. Antiepileptic agents
Several antiepileptic agents are known to have an effect on weight gain [33]. However, two
newer antiepileptic agents, topiramate and zonisamide, have shown an associated decrease in
weight in patients taking these medications [34]. Therefore, these two drugs are being looked
at as potential anorectic agents.
2.2.1. Topiramate (Topamax®)
Topiramate is a carbonic anhydrase inhibitor (Figure 1c) that is typically used in the treatment
of migraines and as an anticonvulsant [35]. Topiramate is proposed to exert its antiepileptic
activity via gamma-aminobutyric acid (GABA)-A-mediated inhibition via a benzodiazepine
insensitive pathway, although the drug also blocks voltage dependent sodium channels
[35-37]. Weight loss has been a commonly reported adverse effect of topiramate; therefore, the
drug has recently come into focus as a potential anorectic agent [38-42]. Topiramate has shown
promise as a combination low-dose therapy with phentermine (Qsymia(R) (originally
Qnexa(R), Vivus Pharmaceuticals, Mountain View, CA, USA) for long term treatment of
obesity [43-46]. Despite, safety concerns related to teratogenicity and cardiovascular effects,
the product has recently been approved by the U.S. Food and Drug Administration.”
Drug interactions with topiramate include coadministration with other antiepileptic agents.
Although no changes in carbamazepine or phenytoin levels were seen, topiramate levels
decreased by 40% or 48%, respectively [35]. However, there have been two case reports of
antiepileptic drug intoxications in patients initiated on topiramate who were already taking
the maximum carbamazepine dose [47]. Decrease in carbamazepine dosage resolved the
interaction. Hyperammonemia, hypothermia and potentially encephalopathy can result from
a synergistic interaction between topiramate, valproic acid, and phenobarbital, although the
exact mechanism of this interaction is unknown [35, 48-50]. Levels of ethinyl estradiol can be
significantly decreased in patients taking topiramate as an adjunctive therapy with valproic
acid [35]. As a carbonic anhydrase inhibitor, topiramate can cause metabolic acidosis, and
therefore is contraindicated in patients taking metformin, while patients taking other carbonic
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anhydrase inhibitors should be monitored due to the potential additive effects when coadmi‐
nistered with topiramate [51-55]. High doses of topiramate (600 mg/day) can increase systemic
exposure to lithium. However, since topiramate dosage proposed to anorectic effects is low,
this interaction may not be a significant concern when used as anti-obesity treatment [56]. No
clinical studies or case studies are available for interactions with CNS depressants (e.g alcohol),
although combined use is contraindicated by the manufacturer due to combined CNS
depression [35]. No data supporting herb-drug interactions are available specifically related
to use of topiramate at low doses as an anorectic agent [27].
2.2.2. Zonisamide (Zonegran®)
Zonisamide (Figure 1d), a methanesulfonamide, is an antiepileptic agent which has broad
spectrum activity and has proven to be useful in patients not responding to other antiepileptic
treatments [57]. The drug blocks sustained and repetitive neuronal firing by blocking voltage
sensitive sodium channels and decreasing voltage sensitive T-type calcium channels [58, 59].
Additionally, it was found that zonisamide has dopaminergic and serotonergic activity, which
contributes to the anorectic effects of the drug [60, 61]. In one randomized placebo-controlled
trial, 30 subjects were administered zonisamide 100 mg daily along with a low calorie diet (500
kcal/day) for a period of 16 weeks. Dosage was increased to up to 600 mg/day for patients not
losing >5% of their initial body weight within the first 12 weeks. The zonisamide group lost
significantly more body weight at the end of the trial compared to the placebo group (approx.
6% loss vs. 1% loss) [62].
Zonisamide is metabolized by the cytochrome P450 3A4 system and therefore can potentially
interact with other drugs metabolized via this route. In one study, the half-life of zonisamide
(t½ = 60 h) was decreased in patients receiving both zonisamide and phenytoin (t½ = 27 h),
carbamazepine (t½ = 38 h, and sodium valproate (t½ = 46 h) [57, 63]. Another study in the dog
demonstrated decreased plasma levels of zonisamide during administration of phenobarbital
[64]. However, any associated decrease in levels of other antiepileptic drugs was not found to
be clinically significant [65, 66]. Cigarette smoking may alter the pharmacokinetics of zonisa‐
mide. Coadministration of carbonic anhydrase inhibitors may increase risk of metabolic
acidosis and kidney stone formation, therefore monitoring is recommended in this patient
population [66]. One study on the effects of cigarette smoke on zonisamide concentrations in
rats suggests that cigarette smoke may decrease plasma levels of the drug due to decreased
oral absorption [67]. Brain, but not plasma levels of zonisamide may be affected by chronic
ethanol consumption. In one study inbred EL mice were administered zonisamide 75 mg/kg
for 1 – 4 weeks along with 10% ethanol ad libidum. In groups with 4 week coadministration,
representing chronic use of alcohol, a decrease in zonisamide brain concentrations, but not
serum concentration were observed [68].
2.3. Orlistat (Xenical®, Alli®)
Orlistat (Figure 1e) is a gastrointestinal lipase inhibitor approved both as a prescription
(Xenical®) and over-the-counter (Alli®) weight loss aid in the long term treatment of obesity
[69]. The drug exhibits antiobesity activity by inhibiting the absorption of dietary fat from the
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lumen of the stomach and small intestine through covalent binding with gastric and pancreatic
lipase active serine residues [70]. Multiple randomized controlled trials have reported
significant weight loss in patients taking orlistat compared to placebo controlled groups. One
meta-analysis cites mean weight loss compared to control of -2.59 kg [95%CI, -3.46 to -1.74] or
-2.9 kg [95%CI, -3.2 to -2.5] over 6 or 12 months, respectively, with a corresponding decrease
in waist circumference, blood pressure, and blood glucose and lipid profiles [71-73].
A large number of preclinical and clinical studies and case reports related to potential drug
interactions with orlistat have been published. There have been several cases of orlistat
interaction with cyclosporine [74-79]. In all cases, significant decreases in plasma cyclosporine
levels were observed following adjunct treatment with orlistat for cyclosporine-associated
weight gain. Although one proposed mechanism for the reduction in plasma cyclosporine is
a decrease in drug absorption, decreased levels may be due to rapid gastrointestinal transit
time resulting from contraindicated high fat diets rather than a true drug-drug interaction [80].
Because orlistat is designed to inhibit gastrointestinal lipases, theoretically absorption of
lipophilic molecules would also be inhibited [81-83]. In one open-label, placebo-controlled
randomized two-way crossover study, orlistat (120 mg) was administered to 12 healthy
subjects three times daily for 9 days followed by administration of Vitamin A (25,000 IU) or
Vitamin E (400 IU) [82]. Although no effect was seen on Vitamin A levels, a significant
reduction in Cmax (approx. 43%) and AUC (approx. 60%) were observed for Vitamin E,
suggesting impaired absorption of Vitamin E by orlistat. In another study, approximately a
30% reduction in beta-carotene levels was observed after administration of orlistat (120 mg)
for four days followed by administration of 0 – 120 mg of beta-carotene three times a day for
six days [83]. Absorption of lipophilic drugs such as the CNS agent lamotrigene can also be
affected by orlistat. In one report, increased frequency of seizures was reported in an 18 year
old female taking lamotrigene following initiation of an orlistat regimen [84]. One case of
hypothyroidism in thyroid carcinoma was reported, presumably due to decreased absorption
of thyroxine [85]. Although orlistat was not found to alter warfarin kinetics per se, but the drug
may alter absorption of the fat soluble vitamin K which can have an effect warfarin levels and
therefore these patients should be monitored for changes in coagulation parameters [86].
2.4. Rimonabant (Acomplia®, Zumulti®)
Rimonabant (Figure 1f) is a cannabanoid receptor antagonist that suppresses appetite by
preventing activation of CB1 receptors by the endogenous cannabanoids anandamide and 2-
arachidonoyl-glycerol [87]. In clinical trials the drug resulted in improvement of multiple
endpoints associated with obesity and metabolic syndrome compared to control groups
including significant weight loss, reduction in waist circumference, decreased triglycerides,
blood glucose, fasting insulin, and leptin levels with increased HDL cholesterol and adipo‐
nectin levels [88-96]. Although rimonabant proved a potentially successful drug in the
treatment of obesity, especially given lack of cardiovascular risks compared to other weight
loss drugs (see Sibutramine below), the drug has not been approved by the U.S. Food and Drug
Administration (FDA). Additionally, although the drug was initially approved in 2006 by the
European Medicines Agency (EMEA), later studies indicating serious neuropsychiatric
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adverse events, especially related to increased risk of suicide, caused the Agency to rescind
the approval in 2009. Although rimonabant is not available in most major markets, ongoing
investigations surrounding the development of the drug continue, while the drug has been
approved in other markets [97-100]. Additionally, the drug appears to be available readily via
online pharmacy services and has been identified as an adulterant in dietary supplements
marketed for weight loss (see Adulteration of Dietary Supplements below) [101-103].
Given the limited and short-lived approval status of rimonabant, there is little information
regarding potential drug-drug and herb-drug interactions available. According to package
insert data submitted to the EMEA, rimonabant is known to be eliminated hepatically and into
the bile by amidohydrolase and CYP3A4, with a 104% increase in rimonabant AUC (95% CI
40 – 197%) upon coadministration of ketoconazole [92, 96, 104, 105]. Therefore, the manufac‐
turer indicated potential interactions with strong CYP3A4 inhibitors (e.g. ketoconazole,
itraconazole, ritonavir, telithromycin, clarithromycin, and nefazodone) and inducers (e.g.
rifampicin, phenytoin, phenobarbital, carbamazepine, and St. John’s Wort). Because rimona‐
bant can decrease levels of fasting insulin and blood sugar, use of rimonabant in diabetic
patients taking anti-diabetic agents is cautioned [92, 96, 104, 105].
2.5. Sibutramine (Meridia®, Reductil®)
Sibutramine hydrocholoride (Figure 1g), and its active primary (M1) and secondary (M2)
metabolites, is a selective serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine
reuptake inhibitor [106-110]. Clinical data supported the efficacy of sibutramine as a weight
loss agent, reporting significant weight loss compared to placebo for patients taking at least
10 mg/day for up to one year [107, 110-114]. The drug was approved as an anti-obesity agent
in 1997 by the U.S. FDA and in 2002 by the EMEA, despite evidence of increased risk of
hypertension and tachycardia, with a requirement that additional post-marketing safety data
be collected relative to cardiotoxicity. As a result, the SCOUT (Sibutramine Cardiovascular
OUTcomes) trial was implemented, which enrolled 10,000 overweight or obese patients aged
55 and older with coexisting diabetes and/or heart disease in a randomized controlled trial
with a 6-month lead in period [115-118]. At the end of the six year study period, data showed
a significant decrease in body weight compared to placebo but increased cardiovascular
morbidity in the randomized sibutramine group [115-118]. Following publication of the
SCOUT trial results in 2010, the EMEA and most other major markets pulled sibutramine while
the United States and Australia required stricter labeling. By 2011 sibutramine was pulled from
all major markets globally. However, as with the case of rimonabant (see above), sibutramine
is of note since it is the primary contaminant found in dietary weight loss supplements (see
Adulteration of Dietary Supplements below).
Sibutramine is known to be metabolized by CYP 3A4 into two active metabolites (M1 and M2).
Data reported by the manufacturer in limited clinical trials (n = 12 – 27 patients) suggest
potential pharmacokinetic changes in AUC and Cmax for sibutramine when taken in combina‐
tion with CYP 3A4 inhibitors such as cimetidine, ketoconazole, erythromycin, simvastatin, and
omeprazole; while sibutramine does not generally have a significant impact on the levels of
these drugs in return [106]. Because of the role of CYP 3A4 in sibutramine elimination, use of
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the drug with other CYP 3A4 substrates, including coadministration with grapefruit juice, is
contraindicated [111]. One case report describes a possible interaction between sibutramine
and citalopram in a 43 year old female patient who experienced hypomanic symptoms shortly
after adding 10 mg sibutramine to her current citalopram and fluoxetine regimen [119].
Symptoms ceased within one day of discontinuing sibutramine. Although the exact mecha‐
nism of the interaction is unknown, the author hypothesized a possible amphetamine-like
hypomania or serotonin syndrome due to increased brain serotonin levels via the combination
of a serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor. Another
case report notes a possible interaction between sibutramine and cyclosporine in a 26 year old
transplant patient resulting in significant increases in cyclosporine trough plasma levels, likely
due to inhibition of CYP 3A4 metabolism [120]. Coadministration of α2 adrenergic blockers,
such as the herb yohimbine, with sibutramine has been recognized as potentially life threat‐
ening due to potential sympathetic side effects resulting in hypertension and tachycardia [121].
Due to the potential risk of bleeding caused by sibutramine, the drug should be used with
caution in patients taking warfarin and other anticoagulants [106].
3. Herbs and dietary supplements used in weight loss
3.1. Açaí (Euterpe oleracea)
The açaí berry is harvested from the palm species Euterpe oleracea and is used mainly for dietary
consumption as whole fruit, juice, or as a flavoring and coloring agent [27]. The fruit, widely
used in Brazil, has gained in popularity as a food product and dietary supplement in the past
several years, mainly due to its antioxidant and anti-inflammatory effects related to high
polyphenol content [122-126]. Although there is little scientific evidence to support the berry for
any of its purported health benefits, it can be found in several dietary supplements promoted
for weight loss. In a pilot study investigating the effect of açaí supplementation on metabolic
parameters in healthy overweight patients, the authors found a significant decrease in fasting
glucose, insulin and cholesterol levels and a mild decrease in LDL-cholesterol and ratio of total
cholesterol to HDL-cholesterol [127]. However, the authors did not assess weight loss in this
study and therefore the activity of açaí as an anorectic agent cannot be determined. There have
been no reported adverse drug interactions or interactions with others herbs and açaí [27].
3.2. Bitter orange (Citrus aurantium, Citrus naringin, synephrine)
Bitter orange is the fruit of Citrus aurantium or Citrus naringin, used as both a food product and
the medicinal properties of the juice and peel [27]. There are multiple active constituents in
bitter orange including several flavonoids (e.g. naringin) and the adrenergic agonists syn‐
ephrine and octopamine [128-134]. Synephrine is structurally similar to ephedrine, therefore
prompting the replacement of ephedra with bitter orange in weight loss supplements,
although the fruit has been used dichotomously as both an appetite stimulant and for weight
loss [27]. However, there is insufficient evidence to confirm the efficacy of bitter orange as an
anti-obesity agent, especially given its inclusion in combination products [27].
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Interactions with bitter orange are varied. Synephrine, like ephedrine, is known to cause
adverse cardiovascular effects at high doses, the risk of which are heightened when combina‐
tion products also including caffeine are ingested and therefore patients taking cardiac
medications should be cautioned on its use [135, 136]. Some evidence demonstrates that bitter
orange can inhibit cytochrome P450 3A4, although to a lesser extent than with grapefruit
[137-140]. A 76% increase in AUC was observed following administration of 10 mg extended
release felodipine administered with 240 mL Seville orange juice compared to control [139];
while a significant increase in indinavir tmax was observed with administration of 8 ounces of
Seville orange juice compared to control [140]. Because synephrine and octopamine, both
endogenous substances, can interact with monoamine oxidase there is a theoretical interaction
of bitter orange with MAOIs [141, 142].
3.3. Caffeine-containing herbs
Caffeine is a methylxanthine that is commonly found in food, beverages, and dietary supple‐
ments. It is used as an additive in beverages and dietary supplements for its energy enhancing
properties. Many dietary supplements marketed for weight loss contain high levels of caffeine,
often from multiple sources, for increased thermogenesis and lipid metabolism [143, 144]. Most
studies investigating the anti-obesity effects of caffeine have been done using combination
products that include ephedra, or have looked at enhancement of athletic endurance [145-151].
Therefore, it is difficult to assess the effect of caffeine alone on weight loss. One study dem‐
onstrated an increase in thermogenic metabolic rate in subjects drinking coffee along with food,
compared to ingestion of decaffeinated coffee [144].
Adverse effects associated with caffeine consumption include restlessness, jitteriness, anxiety,
insomnia, and cardiovascular effects [152-156]. Most drug and herb interactions with caffeine
are mild to moderate and are related to increased adverse effects resulting from decreased
caffeine elimination or additive effects with other methylxanthine containing products [157].
For example, estrogen drugs (e.g. oral contraceptives and estrogen replacement therapy) have
been shown to decrease clearance of caffeine up to 50 – 65% [158, 159]. The most significant
caffeine interaction occurs with coadministration of Ephedra or ephedrine containing products
(see Ephedra below). The ban on ephedra in the United States has resulted in marketing of
“ephedra-free” dietary supplements using ephedra alternatives, including caffeine containing
herbs and bitter orange (see Bitter Orange above). In one randomized controlled trial study,
subjects were administered products containing Citrus aurantium standardized to either a high
dose of synephrine (46.9 mg) or a product containing caffeine and a low synephrine dose (5.5
mg) [136]. A significant increase on blood pressure was observed in patients taking the product
containing both caffeine and synephrine, but not high dose synephrine alone, suggesting an
interaction between the two herbs.
3.3.1. Green tea (Camellia sinensis; EGCG)
Green tea has gained in popularity for the treatment of a wide variety of diseases and for
promotion of general wellbeing. The addition of green tea to weight loss supplements is due
in part to the caffeine content of Camellia sinensis. However, in addition to alkaloid content
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(caffeine, theobromine, theophylline) green tea also contains polyphenols, most notably the
catechin epigallocatechin-3-gallate (EGCG) [160-164]. EGCG, in concert with caffeine, is
proposed to elicit anti-obesity effects via inhibition of catechol O-methyl transferase and
phosphodiesterase [164]. A meta-analysis of clinical trials involving green tea in weight loss
concluded that weight loss is decreased, relative to placebo, in treatment involving both green
tea ECGC and caffeine but not with decaffeinated green tea products [165].
As expected, the majority of drug interactions associated with green tea are related to caffeine
content. However, a few interactions described in the literature are due to other constituents
of green tea. Green tea may be contraindicated, especially at high doses, in patients taking
anticoagulants such as warfarin due to the high Vitamin K content of the herb. There is one
case report of a patient taking warfarin who experienced a significant reduction in INR
following initiation of daily consumption of one-half to one gallon of green tea [166]. Once
green tea consumption was stopped INR normalized. Green tea is also thought to cause
decreased estrogen levels and combination products containing the herb have been used to
improve fertility and relieve menopausal symptoms [167-170]. Therefore, use of high doses of
green tea in patients taking oral contraceptives or estrogen replacement therapy may be
cautioned.
3.3.2. Guarana (Paullinia cupana)
Guarana (Paullinia cupana) is a plant native to South America that is used traditionally and in
anti-obesity supplements for its high caffeine content, although other minor constituents
including theophylline, theobromine, catechin and epicatechin are found in these extracts
[171-176]. There are no studies investigating the effects of Guarana alone on weight loss so it
is difficult to determine the anti-obesity properties of the herb. In one double-blind, parallel,
placebo controlled trial 47 subjects were administered three capsules containing yerba mate
(Ilex paraguayensis, 112 mg), guarana (95 mg) and damiana (Turnera diffusa, 36 mg) daily for 45
days, resulting in significant weight loss (-5.1 ± 0.5 kg) compared to placebo (-0.3 ± 0.08 kg)
[145]. One of the few interactions reported with guarana not related to caffeine content suggests
possible interference with anticoagulants since platelet aggregation was observed in vitro and
in animal studies [177].
3.4. Dandelion (Taraxacum officinale)
Dandelion is a perennial herb of multiple global varieties that has traditionally been used for
liver, spleen, kidney, and gastrointestinal disorders, although there have been no clinical trials
investigating the effects of dandelion in weight loss [27, 178]. It is commonly added to weight loss
supplements, mainly for its diuretic properties, although the herb does possess some mild laxative
properties [179-181]. There are no known drugs interactions between Taraxacum and other herbs
or drugs, although one study in rats suggests a probable interaction with quinolone antibiotics
due to the high mineral content of Taraxacum [182]. In the study, ciprofloxacin (20 mg/kg) Cmax
significantly decreased while Vd and t½ significantly increased when administered with crude
dandelion extract (2 g/kg) compared to control. There is one case report of hypoglycemia in a 58
year old diabetic patient following a 2-week period of dandelion consumption in salads [183].
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The patient denied changes in calorie consumption, exercise, or insulin dosing. Diabetic patients
taking hypoglycemic agents while consuming dandelion should be monitored.
3.5. Ephedra (Ephedra sinica, ma huang)
Ephedra, derived from the evergreen shrub Ephedra sinica, contains multiple plant alkaloids
including ephedrine and pseudoephedrine that are chemically related to amphetamines. These
compounds act by increasing availability and activity of endogenous neurotransmitters such
as epinephrine and norepinephrine, resulting in brain and cardiovascular catecholamine
receptor stimulation [184]. The herb has traditionally been used for bronchodilation in the
treatment of respiratory ailments such as asthma, as an athletic performance enhancer, and for
its thermogenic properties in weight loss [148, 185-189]. Ephedra as a weight loss dietary
supplement is commonly found in combination products also containing caffeine or caffeine-
containing herbs. In one study a product containing 90 mg and 192 mg of ephedra alkaloids
and caffeine, respectively, administered daily over six months in a randomized, double-blind
placebo controlled trial resulted in significant decreases in body weight, body fat and LDL-
cholesterol with an increase in HDL-cholesterol [148]. The addition of aspirin to ephedrine
containing products can potentiate the thermogenic properties of ephedra, improving weight
loss compared to products containing ephedra alone [190-201]. Due to high risk of cardiovas‐
cular toxicities and cardiomyopathies, ephedra has been banned in the United States [202-211].
However, the herb is still available in other countries [212].
Because of the controversial nature of ephedra related to cardiac toxicity and its eventual ban
via the U.S. FDA, there are a significant number of clinical studies and case reports related to
toxicities and interactions with ephedra and ephedrine. Ephedra can potentially interact with
anesthetics since it is known that administration of ephedrine can reverse anesthesia induced
hypotension and regression of analgesia following epidural blockade [213, 214]. Ephedrine
has both chrontropic and inotropic effects, and therefore interactions with cardiovascular
agents may be possible [184, 211, 215, 216]. However, no effects on heart rate or blood pressure
were seen in clinical trials investigating the efficacy of ephedra in weight loss [192, 217, 218].
Theoretically interactions with antiadrenergic agents and MAOIs can occur due to sympatho‐
mimetic effects of ephedrine, potentially increasing risk of hypertensive crisis. There is a case
report of a patient taking a product containing caffeine, ephedrine, and theophylline who
experienced multiple adverse effects including encephalopathy, hypotension, tachycardia,
and hypothermia 24 hours following discontinuation of phenelzine [219]. Interactions with
ephedrine and tricyclic antidepressants are also possible [220]. Some evidence from clinical
trials suggests that ephedra in combination with caffeine can cause hyperglycemia, and
therefore interactions with antidiabetic agents is possible [147, 148, 221]. A lowering of seizure
threshold has been observed in patients taking ephedrine, and therefore use of ephedra in this
patient population is cautioned [222]. A major interaction between ephedra and methylxan‐
thines (e.g. caffeine, theophylline) is possible due to increased risk of cardiovascular, neuro‐
logic and psychiatric adverse effects due to additive sympathomimetic and CNS stimulant
activity [184, 223, 224]. One case study reports a 21 year old male patient admitted to the
hospital emergency room with a blood pressure of 220/110 mmHg and ventricular arrhythmia
following ingestion of a caffeine/ephedra containing product (“Herbal Ecstasy”) [225].
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3.6. Glucomannan (Amorphophallus konjac)
Glucomannan is a soluble but highly viscous dietary fiber derived from the root of the
Amorphophallus konjac (elephant yam) plant that grows native to Asia [27]. Although tradi‐
tionally used as a food, the plant has gained popularity as an additive in weight loss supple‐
ments since the dietary fiber absorbs water in the gastrointestinal tract, helping to promote a
sense of satiety and act as a bulk laxative [226-228]. There is also evidence that fiber content of
glucomannan helps to reduce cholesterol levels [67, 229-232]. In a double blind crossover study
involving 63 healthy males, 3.9 grams of glucomannan administered daily for four weeks
resulted in a 10% reduction in total cholesterol, 7.2% reduction in LDL cholesterol, and a 23%
decrease in triglyceride levels [67]. A meta-analysis of clinical trials involving glucomannan
reported overall decreases in the above markers as well as fasting blood glucose [230].
There are relatively few reported drug interactions with glucomannan, most of which are likely
due to associated decreases in cholesterol and lipid levels as well as interference with absorp‐
tion of some drugs. Monitoring of patients taking antihypertensives, antilipemics, and other
anti-obesity agents is warranted. Several studies note a significant decrease in fasting blood
glucose levels following glucomannan administration while decreased absorption of the
sulfonylurea drugs is possible [230, 231, 233-237]. Glucomannan can significantly decrease
circulating levels of T3, T4, and FT3 in the treatment of thyrotoxicosis and therefore its use
may be contraindicated in patients taking thyroid medications [238]. Glucomannan can
potentially affect the absorption of certain drugs and supplements as demonstrated in one
study in which absorption of the fat soluble Vitamin E was decreased potentially via the
reduction of bile acids necessary for absorption of the vitamin [239].
3.7. Hoodia gordonii
Hoodia gordonii, a small succulent of the Apocynaceae family native to the Kalahari Desert,
has been used traditionally by native tribes for its appetite and thirst suppressing proper‐
ties [240, 241]. The active constituent of Hoodia (P57 or P57AS3) is an oxypregnane steroi‐
dal glycoside which is purported to increase ATP production in the hypothalamus, resulting
in a feeling of satiety [242]. There is little known regarding potential drug or herb interac‐
tions  with  Hoodia,  although  in  vitro  studies  suggest  a  potential  interaction  with  drugs
metabolized by CYP 3A4 [243].
3.8. Hydroxycitric acid (HCA, Garcinia cambogia)
Garcinia cambogia is a plant native to Southeast Asia which yields a small purple fruit used in
weight loss products for its hydroxycitric acid (HCA) content [27, 244]. The anorectic activity
of HCA is due to the inhibition of the adenosine triphosphate-citrate (pro-3S)-lyase, which
catalyzes the formation of acetyl-CoA, resulting in decreased fatty acid synthesis and lipo‐
genesis [245]. The evidence for HCA as an effective weight loss agent is contradictory. One
randomized controlled trial reported a 5-6% reduction in weight and BMI following approx‐
imately a 4.5 gram daily dose of HCA, while two other studies reported no significant weight
loss or effect on appetite at lower doses of 1.5 – 2.4 gram daily HCA doses [246-248]. There are
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a minimal number of reported interactions with Garcinia or HCA. Antilipemic agents such as
HMG-CoA reductase inhibitors should be avoided due to an increased risk of rhabdomyolysis.
In one case report a healthy 54 year old female patient reported chest pain following ingestion
of an herbal product containing ephedra, guarana, chitosan, Gymnena sylvestre, Garcinia
cambogia (50% HCA), and chromium. Lab results indicated elevated serum creatine kinase
(1028 IU/mL), which declined following cessation of the supplement [249]. Although the exact
interaction was not determined, cautionary use of HCA-containing products in patients at risk
of rhabdomyolysis is warranted.
3.9. Herbal laxatives
Frequently laxatives and diuretics are used alone or in combination products to promote
weight loss. However, there is little to no evidence supporting these supplements as anti-
obesity agents, although subgroups of this patient population may abuse laxatives and
diuretics for the purpose of weight loss [250].
3.9.1. Bulk laxatives
Bulk laxatives generally consist of soluble dietary fiber which expands in the gastrointestinal
tract in the presence of water resulting in improved bowel function. Common sources of bulk
laxatives include Amorphophallus konjac (glucomannan, see above), guar gum (Cyamopsis
tetragonoloba), and psyllium husk (Plantago psyllium). Although the efficacy of bulk laxatives
for weight loss is not proven, adsorption of dietary glucose and lipids to these agents in the
gastrointestinal tract results in decreased absorption of lipids, cholesterol, and carbohydrates
into the body, thereby promoting weight loss [230, 234, 251-253]. Because of changes in
carbohydrate and glucose absorption, dosing of antidiabetic agents may require modification
and therefore patients in this population should be monitored when taking bulk laxatives
[254-261]. Bulk laxatives appear to have some effect on the absorption of orally administered
medications, which can result in changes in drug plasma levels [262-272]. For example, in one
study the effect of guar gum on digoxin and phenoxymethyl penicillin absorption was studied
in 10 healthy volunteers, with significant reductions in both peak penicillin plasma concen‐
trations and AUC, but little effect on overall digoxin levels [269]. In one case report of a patient
with adrenal insufficiency treated with fludrocortisone and prednisolone, the patient experi‐
enced symptoms of acute adrenal crisis including fatigue, nausea, abdominal pain, and
weakness approximately 3 – 4 days after initiation of psyllium [262]. The authors postulated
that psyllium inhibited absorption of fludrocortisone and/or prednisolone. Other evidence
related to changes in absorption of ethinyl estradiol, metformin, and lithium have also been
reported [264-266, 270, 272].
3.9.2. Stimulant laxatives
Stimulant laxatives act by irritating the lining of the gastrointestinal tract, resulting in increased
propulsive muscle contractions that aid elimination of intestinal contents. Because of the quick
and efficacious activity, stimulant laxatives are most frequently abused to promote weight loss
by increasing gastrointestinal transit time [273, 274]. The most common stimulant laxative
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herbs are senna (Cassia senna), aloe latex (Aloe vera), and Cascara sagrada (Frangula purshiana).
The leaves and pods from Cassia senna contain anthroquinone stimulant laxative compounds
effective in the treatment of constipation and for bowel evacuation prior to medical procedures
[27, 275-295]. The herb has been approved by the U.S. FDA as a non-prescription medication.
Similarly, aloe latex, derived from the peripheral bundle sheath cells of the aloe leaf, contains
anthracene compounds that are cleaved in the colon by bacterial enzymes into active anthrone
compounds with stimulant laxative properties [296-299]. However, concerns over possible
carcinogenic properties of certain anthraquinones in aloe latex, along with lack of safety
evidence, prompted the U.S. FDA to ban aloe latex in 2002, although the herb is still used in
other countries [178, 300, 301]. The bark of the deciduous buckthorn shrub Cascara sagrada is
effective for the treatment of constipation due to the stimulant laxative properties of its
anthraglycoside constituents [27, 302]. Like aloe latex, Cascara had previously been approved
by the U.S. FDA as a non-prescription medication, but the designation was withdrawn into
2002 based on lack of safety and efficacy evidence, although the herb is still available as a
supplement [300].
Stimulant laxatives share multiple common adverse effects and potential drug interactions.
Because of decreased gastrointestinal transit time, absorption of some drugs, especially those
with poor permeability, may be decreased [303, 304]. Experimental evidence in rats suggests
absorption of carbohydrates may result in decreased blood glucose levels and therefore
monitoring of patients receiving hypoglycemic agents or insulin is warranted [305-307].
Concomitant use of stimulant laxatives with diuretics, cardiac glycosides and licorice is
contraindicated due to hypokalemic effects, especially with long term use of these laxatives
[27, 178, 304, 308, 309]. Senna can potentially interfere with antiplatelet and anticoagulant
activity by causing excessive bleeding [310]. There is one case report of a possible interaction
of aloe and sevoflurane, in which a 35 year old female patient undergoing surgery for heman‐
gioma experienced perioperative bleeding [311]. Although the size and vascularization of the
hemangioma were noted as partial root causes of the bleeding episodes, the authors felt that
the combination of anesthetic and aloe administration (4 tablets daily for 2 weeks prior to
surgery) may have contributed to the adverse event.
3.10. Licorice (Glycyrrhiza glabra)
Licorice has historically been used both medicinally and as a food product and its relative
safety at low doses has placed it on the U.S. FDA GRAS (generally recognized as safe) list,
although  at  high  doses  licorice  can  cause  severe  adverse  effects  [27].  The  main  active
components of licorice are glycyrrhizin and glycyrrhizic acid, although several other active
constituents have been identified [312, 313]. One of the main adverse effects of high licorice
consumption includes mineralocorticoid excess syndrome and resulting hypokalemia with
associated  increases  in  blood  pressure,  as  well  as  secondary  pseudohyperaldosteronism
[314-338]. Licorice consumption may also alter blood glucose levels, potentially via binding
to PPAR-γ [339,  340].  Although licorice  is  used in  dietary supplements  for  weight  loss,
contradictory evidence reports weight gain with licorice consumption [341-343]. However,
one study in which 3.5 grams daily licorice consumption was administered to 15 normal
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weight subjects for two months reports a significant decrease in body fat mass but not body
mass index [344, 345].
Acquisition of mineralocorticoid excess syndrome following high dose consumption of licorice
results in the potential for licorice-drug interactions with multiple drug classes, including
aldosterone receptor antagonists, antiarrhythmics, antihypertensives, cardiac glycosides,
corticosteroids, diuretics, and potassium lowering agents [321-324, 326]. In one study, 10
healthy subjects were given 32 grams of licorice daily for two weeks along with 25 mg of
hydrochlorothiazide (HCTZ); a significant reduction in potassium levels was observed, while
two patients experience hypokalemia, compared to HCTZ alone [346]. Glycyrrhizin and β-
glycyrrhetinic acid may also affect complement activity and decrease neutrophil generated
oxides and peroxides, resulting in anti-inflammatory activity [347-350]. Therefore, licorice
should be used with caution in patients taking other anti-inflammatory medications. Licorice
constituents may also have an effect on hormonal agents via anti-estrogenic activity, inhibition
of 17β-hydroxysteroid dehydrogenase, or associated decreases in prolactin levels [351-358]. In
in vitro and animal studies it has been shown that constituents in licorice can promote the
intestinal absorption of some drugs and therefore it is recommended that oral drugs be taken
at least an hour before or two hours after licorice consumption [359]. Theoretically licorice may
interact with antidepressant agents, since increases in norepinephrine and dopamine have
been observed in mice while in vitro cell culture studies suggest potential serotonin reuptake
inhibition [360, 361].
3.11. St. John’s Wort (Hypericum perforatum)
St. John’s Wort (SJW) is a perennial herb native to Europe that is commonly used to treat
depression, anxiety, post-menopausal symptoms, attention deficit hyperactivity disorder
(ADHD), and other mood disorders [362-367]. The active constituents of SJW are hypericin
and hyperforin, which are thought to act by inhibiting the synaptic uptake of serotonin (5-HT),
GABA, noradrenaline, dopamine, and L-glutamate via a novel mechanism compared to
synthetic antidepressants [362, 368-373]. Although there are no official studies regarding the
use of SJW for weight loss, anecdotal reports suggest a positive effect on satiety, which may
be attributable to the serotonergic uptake inhibition (see Sibutramine above). Following the
removal of fenfluramine, an anorectic agent commonly used in the combination product
“Phen-Fen” (phentermine – fenfluramine), from the market in 1997, SJW was combined with
Ephedra or Citrus aurantium (see above) and marketed for weight loss as “Herbal Phen-Fen”.
Because of the expanding popularity of SJW in the 1990s – 2000s, a great deal of research on
the mechanism of action and herb-drug interactions has been reported.
Drug interactions with SJW are primarily related to binding of active constituents to the
pregnane X receptor leading to induction of cytochrome P450 metabolizing or induction of p-
glycoprotein efflux mechanisms via the MDR-1 drug transporter [374-388]. As a result,
pharmacokinetics of many cytochrome P450 drug substrates is altered, often leading to
decreased plasma concentrations and reduced efficacy [27]. There have been numerous studies
that have demonstrated potential metabolism-related drug interactions with CYP 3A4, 1A2,
2C9 and 2C19 [389]. Kinetics of antiplatelet and anticoagulant agents may be altered in the
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presence of SJW [390, 391]. In one open-label, three-way crossover randomized study, 12
healthy male subjects were given 1 gram of SJW (standardized to hypericin 0.825 mg/g and
hyperforin 12.5 mg/g) for 21 days, with administration of a single 25 mg dose of warfarin on
day 14 [390]. A significant increase in warfarin (Cl/F) was observed compared to warfarin
alone, with a corresponding decrease in AUC and half-life. However, there was no significant
impact on INR or platelet aggregation. The interaction is likely caused not only by alteration
of drug metabolism via CYP 450 induction, but also binding of warfarin to the SJW constituents
hypericin and pseudohypericin, leading to decreased absorption of the drug [392]. In another
study, patients not responding to clopidogrel therapy alone experienced an increase in
therapeutic activity when clopidogrel and SJW were coadministered; therefore it is possible
that patients responding to stand alone clopidogrel treatment may be at increased risk of
bleeding [391]. There has been one case report of a possible interaction between theophylline
and SJW in which theophylline levels significantly increased following discontinuation of SJW
in a smoker also taking 11 other drugs [393]. However, another study in healthy subjects
showed no impact of SJW on theophylline kinetics [394]. Plasma concentrations of protease
inhibitors such as indinavir may be reduced in the presence of SJW due to induction of p-
glycoprotein efflux in the gastrointestinal tract [395-398]. Decreased plasma levels of the
“statins” simvastatin and atorvastatin have been reported in controlled, randomized, cross‐
over studies [399, 400]. Reports of pharmacokinetic interactions have also been reported for
digoxin, gliclazide, imatinib, irinotecan, methadone, omeprazole, verapamil, and voriconazole
have also been published [401-412]. In general, coadministration of SJW with drugs signifi‐
cantly eliminated via these enzymes should be avoided.
Several studies and case reports describe interactions between SJW and oral contraceptives,
resulting in breakthrough or irregular bleeding and unplanned pregnancy [413-416]. In one
case report, an unwanted pregnancy occurred in a 36-year old patient while taking an ethinyl
estradiol/dinogesterol oral contraceptive (Valette®). The patient had previously been taking
fluvastatin (20 mg/day) for 2 years, but had discontinued the drug and started 1700 mg SJW
extract daily for 3 months prior to conception [414]. One randomized controlled trial in 18
female subjects taking low dose oral contraceptives (0.02 mg ethinyl estradiol / 0.150 mg
desogestrel) in combination with 300 mg SJW twice daily reported a significant increase in
breakthrough bleeding compared to subjects taking oral contraceptive alone [417]. Progestins
and estrogens contained in oral contraceptives are known to be metabolized by various CYP
enzymes and therefore induction of these enzymes by SJW results in decreased plasma
concentrations and therapeutic failure [417-420].
Interactions between SJW and with drugs used in the prevention of organ transplant rejection
such as tacrolimus and cyclosporine have been reported [421-431]. Several transplant patients
have experienced transplant rejection potentially related to coadministration of SJW. In one
case report a patient treated with 75 mg cyclosporine daily for several years following kidney
transplant experienced a drop in cyclosporin plasma levels attributed to SJW administration
[427]. Levels returned to normal when SJW was discontinued and dropped upon rechallenge
with SJW extract. Similarly, tacrolimus plasma levels markedly decreased in a study involving
10 stabilized renal transplant patients administered 600 mg SJW extract for two weeks,
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requiring dosage adjustments during and for up to two weeks following discontinuation of
SJW [431].
SJW may interact with selective serotonin reuptake inhibitors (SSRIs), monoamines, and other
antidepressant and psychiatric medications due to the serotonin uptake inhibitory properties
of hypericin and hyperforin, although metabolic induction plays a role for some drugs [368,
370-373, 432-446]. In one case report, a patient who had been taking paroxetine 40 mg daily for
treatment of depression discontinued her medication and began taking SJW 600 mg daily [434].
No adverse events were reported with the switch, but upon coadministration of a 20 mg dose
of paroxetine to aid in sleep the patient experience extreme grogginess, weakness, fatigue, and
incoherency. The author cited the potential for additive serotonin uptake inhibition resulting
in “serotonin syndrome”. One case of a male adult patient stabilized on methylphenidate for
attention deficit hyperactivity disorder (ADHD) is reported in which the patient experienced
increased ADHD symptoms after taking SJW 600 mg daily for four months [438]. The mech‐
anism of the interaction is unknown. Interactions have also been reported for amitriptyline,
clozapine, fexofenadine, and sertraline; therefore administration of SJW in patients taking
these and similar drugs should be avoided [440, 443, 444, 446, 447].
An interaction between SJW and drugs known to cause phototoxic adverse reactions is also
possible, due to the photosensitizing nature of hypericin [448-450]. In one study, 11 subjects
were exposed to UVA1 radiation at baseline and following 10 days treatment with 1020 mg
(3000 mcg hypericin) extract [449]. Minimum erythemal dose (MED) as measured 8, 24 and
48 hours after exposure to radiation and was found to be significantly lower at 8 and 48,
but not 24 hours, after exposure compared to control. There is one case report of a patient
experiencing severe phototoxicity upon exposure to laser light (532 nm) and pulsed dye
laser light (585 nm), presumably due to ingestion of SJW [451]. SJW may also increase the
sensitivity and skin toxicity of radiation treatment in patients undergoing radiation therapy,
possibly through photosensitizing effects although the exact underlying mechanism is not
known [452].
3.12. Willow bark (Salix alba)
Willow bark from the Salix alba tree is often contained in weight loss supplements, presumably
due to earlier studies that noted enhanced thermogenic properties of ephedra in combination
products also including aspirin (see Ephedra above). The active constituents of white willow
are predominantly the salicylates (acetylsalicylic acid) and, therefore, the bark has traditionally
been used in the treatment of pain [27, 453, 454]. The analgesic and anti-inflammatory activity
of willow bark is due to inhibition of cyclooxygenase-2 (COX-2) mediated prostaglandin E2
release [455, 456]. Although there are few case reports dealing with willow bark extract
specifically, drug and herb interactions seen with other salicylates are possible [455, 457].
Generally, caution should be used in concomitant administration of drugs contraindicated for
aspirin, such as beta-blockers, NSAIDs, carbonic anhydrase inhibitors (e.g. acetazolamide),
probenecid, alcohol, and salicylates, while the kinetics of protein bound drugs can also be
modified [27]. Salicin may also have an effect on platelet aggregation, and therefore interac‐
tions with anticoagulants and antiplatelet drugs are possible [458, 459]. In one randomized
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double-blind study involving 16 patients administered standardized extracts of Salicis cortex
(240 mg salicin/day), mean arachidonic induced platelet aggregation was reduced (61%
compared to 78% in placebo group), but not as significantly as in the acetylsalicylic acid group
(13% reduction) [458]. One randomized placebo-controlled trial investigating the efficacy of
willow bark extract in osteoarthritis reported an increase in triglyceride levels, suggesting a
potential interaction between willow bark and antihyperlipidemics [460]. Some patients in
another randomized controlled trial, who were given 240 mg salicin daily for four weeks,
suffered blood pressure instability and edema; use of willow bark in patients taking antihy‐
pertensives should be cautioned [461].
4. Adulteration of dietary supplements
A final note is necessary regarding the adulteration of weight loss supplements with drug
products and other chemical substances. This adulteration is often the underlying cause for
the purported activity of a dietary supplement and can result in serious toxicity. The most
commonly cited contaminant in weight loss supplements is sibutramine (Meridia®; see above),
a weight loss supplement removed from the market in October 2010 for significant cardiac
toxicities [462-466]. One U.S. FDA report cites 72 different herbal products containing adul‐
terants, 94.4% of which contained sibutramine as an additive [102]. Multiple products listed
in the report were contaminated with phenolphthalein (11.1%) or the anti-seizure drug
phenytoin (2.8%). Other reported contaminants (1.4%) included the experimental anti-obesity
agent cetilistat, the recalled anti-obesity agent rimonabant (see above), the anti-obesity
amphetamine stimulant drug fenproporex, the antidepressant fluoxetine, or the diuretics
furosemide and bumetanide[103]. Phenophthalein was previously used as a laxative in over-
the-counter products but was removed from the U.S. market in 1999 due to concerns of
carcinogenicity and genotoxicity [467]. Another study investigating contamination of 20
different dietary supplements using 1H-NMR methods found contamination of 14 of the
products (70%), with eight products containing sibutramine, five containing both sibutramine
and phenolphthalein, and one formulation containing undeclared synephrine [468]. There
have been other reports of contamination of weight loss supplements with the diuretic
hydrochlorothiazide [462, 469]. Given that tainting of weight loss supplements is common,
patients and health care professionals should be made aware of the risks associated with
ingestion of herbal products, especially those with minimal evidence backing their claims of
efficacy.
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